FY2016 EPS Estimates for Alcobra Ltd. Increased by Jefferies Group (ADHD)
Alcobra Ltd. (NASDAQ:ADHD) – Jefferies Group raised their FY2016 EPS estimates for Alcobra in a report issued on Wednesday. Jefferies Group analyst B. Amin now anticipates that the firm will post earnings per share of ($0.98) for the year, up from their prior forecast of ($1.02). Jefferies Group has a “Buy” rating and a $6.00 price objective on the stock. Jefferies Group also issued estimates for Alcobra’s Q4 2016 earnings at ($0.30) EPS, FY2017 earnings at ($0.97) EPS, FY2018 earnings at ($0.94) EPS, FY2019 earnings at ($1.05) EPS and FY2020 earnings at ($1.11) EPS.
Other research analysts also recently issued research reports about the company. WBB Securities downgraded Alcobra from a “hold” rating to a “sell” rating and reduced their price objective for the company from $5.00 to $4.00 in a research note on Monday, September 12th. Cantor Fitzgerald restated a “buy” rating and issued a $16.00 price objective on shares of Alcobra in a research note on Thursday, September 29th. Barclays PLC started coverage on Alcobra in a research note on Monday, August 1st. They issued an “equal weight” rating and a $8.00 price objective for the company. Stifel Nicolaus downgraded Alcobra from a “buy” rating to a “hold” rating in a research note on Friday, October 7th. Finally, Oppenheimer Holdings Inc. downgraded Alcobra from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $5.14.
Shares of Alcobra (NASDAQ:ADHD) traded down 7.465% on Friday, hitting $2.008. The company had a trading volume of 145,960 shares. The firm’s market capitalization is $55.34 million. Alcobra has a 1-year low of $1.77 and a 1-year high of $6.80. The company has a 50 day moving average price of $2.23 and a 200 day moving average price of $4.02.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings results on Tuesday, November 15th. The company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.02. The company earned $7.90 million during the quarter, compared to the consensus estimate of $4.30 million.
A number of hedge funds have recently modified their holdings of the company. BlackRock Fund Advisors boosted its stake in shares of Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock worth $1,621,000 after buying an additional 6,516 shares during the period. Jefferies Group LLC bought a new stake in shares of Alcobra during the second quarter worth about $533,000. VHCP Management II LLC boosted its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares during the period. VHCP Management LLC boosted its stake in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the period. Finally, Palo Alto Investors LLC boosted its stake in shares of Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock worth $1,225,000 after buying an additional 18,600 shares during the period. 73.72% of the stock is currently owned by institutional investors and hedge funds.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.